The Food and Drug Administration approved Prevnar 20, Pfizer’s next-generation 20-valent pneumococcal conjugate vaccine, for treating infants and children under the age of 17. The announcement ...

The randomized, double-blind trial enrolled a total of 1796 participants, of which 1727 completed the study. Positive topline results were announced from a phase 3 study evaluating the safety and ...

While Pfizer won its competition with Merck to get its next-generation pneumococcal vaccine to the market, it lost its more critical battle in June when the FDA said its rival could administer its ...

With its next-generation pneumococcal vaccine, Pfizer has been playing catch-up with Merck in the indication’s key age group—infants. Thursday, Pfizer got to the finish line 10 months after its rival, ...

Merck’s investigational pneumococcal vaccine V116 matched Pfizer’s Prevnar 20 vaccine in efficacy and safety, according to data from a Phase 3 trial released Tuesday morning. The trial, STRIDE-3, ...

(RTTNews) - Drug major Pfizer Inc. (PFE) announced Wednesday positive top-line results from a Phase 3 study (B7471004) exploring coadministration of Prevnar 20 with seasonal flu vaccine in older ...

The Food and Drug Administration has approved Pfizer’s Prevnar 20 (pneumococcal 20-valent conjugate vaccine) for the prevention of invasive disease and pneumonia caused by the 20 pneumococcus ...

A Pfizer vaccine that addresses 20 types of pneumococcal bacteria has won FDA approval, giving the company a successor to a blockbuster product and the edge in a race to protect against more of these ...

LONDON, Dec 4 (Reuters) - Wyeth is confident its best-selling childhood vaccine Prevnar will remain a key sales driver, despite the arrival of a new competitor from GlaxoSmithKline Plc within the next ...

NEW YORK, Aug 11 (Reuters) - Wyeth said on Tuesday that U.S. regulators will take three months longer than expected to review Prevnar 13, a more-protective new formulation of its Prevnar vaccine used ...